Results 21 to 30 of about 25,234 (166)
Scientific Reports, 2023 The renal protective effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors and renin-angiotensin system (RAS) inhibitors on diabetic nephropathy without albuminuria have not been fully investigated.
Tatsuya Ishibashi +4 more
doaj +1 more source
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Endocrine Connections, 2020 Background and Aims: It is currently unclear whether sodium–glucose co-transporter 2 (SGLT2) inhibitor administration can improve the insulin sensitivity as well as rapidly reduce plasma glucose concentrations in humans during the early phase of ...
Yuka Goto +11 more
doaj +1 more source
How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
Cardiovascular Diabetology, 2020 Sodium–glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for the treatment of patients with type 2 diabetes to reduce the risk of cardiovascular events, including heart failure (HF).
Atsushi Tanaka, Koichi Node
doaj +1 more source
Cardiovascular Diabetology, 2023 Recent type 2 diabetes guidance from the UK’s National Institute for Health and Care Excellence (NICE) proposes offering SGLT2-inhibitor therapy to people with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, and considering ...
Katherine G. Young +6 more
doaj +1 more source
Journal of Pharmacological Sciences, 2018 We aimed to examine the effects of a sodium glucose co-transporter 2 (SGLT2) inhibitor on systemic and intrarenal renin–angiotensin system (RAS) in subtotally nephrectomized non-diabetic rats, a model of chronic kidney disease (CKD).
Lei Li +10 more
doaj +1 more source
Cardiovascular Diabetology, 2020 Background Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and
Hung-Yi Chen +3 more
doaj +1 more source
Journal of Diabetes Investigation, 2021 Aims/Introduction This study aimed to investigate the risk of diabetic ketoacidosis (DKA) in insulin‐treated type 1 diabetes patients administered sodium–glucose cotransporter 2 (SGLT2) inhibitors in real‐world clinical practice. Materials and Methods We
Takeshi Horii +3 more
doaj +1 more source
Renoprotective Effects of SGLT2 Inhibitors
Heart Failure Clinics, 2022 SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption.
openaire +4 more sources
SGLT2 Inhibitor–Induced Sympathoinhibition
JACC: Basic to Translational Science, 2020 Summary: Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression.
Lakshini Y. Herat, PhD +10 more
openaire +2 more sources
Asian Journal of Pharmaceutical Research and Development, 2023 The pharmaceutical industry employs a variety of analytical techniques to test the quality, concentration, and composition of medicines in biological fluids. This review work to provide the most existing analytical methods for the analysis of SGLT2 inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) in active pharmaceutical ingredients, biological
Pravin Dighe, Namrata Kale
openaire +1 more source